Publications by authors named "W Sakamoto"
HER2, a member of the human epidermal growth factor receptor(HER)family, exhibits gene amplification, protein overexpression, or both in 13-27% of gastric cancer(GC)cases. Through the activation of downstream Akt and ERK pathways, HER2 promotes the survival and proliferation of gastric cancer cells. The impact of HER2 signaling on the tumor microenvironment(TME)in GC remains unclear, and the heterogeneity of HER2 overexpression in GC tissues is considered a contributing factor.
View Article and Find Full Text PDFPermanent neonatal diabetes mellitus (PNDM) is a genetic disorder, characterized by a decrease in endogenous insulin secretion. Therefore, exogenous insulin supplementation plays a central role in controlling glycemia. Although adding a sulfonylurea can help to discontinue insulin, discontinuation is sometimes difficult when the sulfonylurea is administered at older ages.
View Article and Find Full Text PDFArticle Synopsis
- Scientists found a group of enzymes in plants that help add a special chemical called acetyl to proteins.
- They studied one of these enzymes called GNAT1 and discovered it’s not needed for a plant's light response, unlike another enzyme called GNAT2.
- The research showed that GNAT1 works well with GNAT2 and another enzyme, GNAT3, suggesting these enzymes work together to control how plants adjust certain chemical processes inside their cells.
Mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) gastric cancer (GC) exhibits an immune-active tumor microenvironment (TME) compared to MMR proficient (pMMR)/microsatellite stable/Epstein-Barr virus-negative [EBV (-)] GC. The tumor cell-intrinsic cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway has been considered a key regulator of immune cell activation in the TME. However, its significance in regulating the immune-active TME in dMMR/MSI-H GC remains unclear.
View Article and Find Full Text PDFArticle Synopsis
- The study explores the use of zolbetuximab, a monoclonal antibody targeting claudin-18 isoform 2 (CLDN18.2), to enhance antibody-dependent cellular cytotoxicity (ADCC) in gastric cancer (GC).
- Despite analyzing its expression, CLDN18.2 did not significantly impact the clinical outcomes of GC patients, although it was positively associated with Epstein-Barr virus (EBV) status and PD-L1 expression.
- The findings indicate that while CLDN18.2 expression and tumor-infiltrating NK cell levels are higher in EBV-associated GC, the overall frequency of immune cells like NK cells and macrophages didn’t differ significantly between CLDN18.2